Beatrice Brunkhorst

Medicine · Health Sciences

17h-index1.3kcitations29works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(9), Cell Adhesion Molecules Research(8), Immunotherapy and Immune Responses(7), Immune Response and Inflammation(6), Neutrophil, Myeloperoxidase and Oxidative Mechanisms(5)

Publications29 total

Data from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Supplementary Figure 1 from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Supplementary Figure 1 from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Data from A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
2023Open Access
Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
Frontiers in Medicine·2020· 9 citedOpen Access
Abstract 2615: Preclinical evaluation and mechanistic characterization of M7824 (MSB0011359C), a novel bifunctional fusion protein targeting the PD-L1 and TGFβ pathways
Cancer Research·2017· 7 cited
Characterizing Programmed Death Ligand 1 (PD-1L) Expression in Merkel Cell Carcinoma
International Journal of Radiation Oncology*Biology*Physics·2016Open Access
Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma
PLoS ONE·2015· 64 citedOpen Access
Cyclophosphamide mechanism of action in preclinical tecemotide studies
Journal for ImmunoTherapy of Cancer·2013Open Access
Abstract 1237: Mechanism of action of L-BLP25 in preclinical pancreatic tumor models.
Cancer Research·2013
Policy on Installation of Wells for Use in Closed-Loop Geothermal Heating Systems
2012
A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
Clinical Cancer Research·2011· 95 cited
huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models
Cancer Immunology Immunotherapy·2006· 68 citedOpen Access
Improvement of Fc–erythropoietin structure and pharmacokinetics by modification at a disulfide bond
Protein Engineering Design and Selection·2005· 39 cited
Engineering a pharmacologically superior form of leptin for the treatment of obesity
Protein Engineering Design and Selection·2005· 34 citedOpen Access
HuBC1-IL12: A very potent immunocytokine which targets the oncofetal fibronectin in the extracellular matrix of tumor vasculature
Cancer Research·2004· 1 cited
Engineering of an IL-2 immunocytokine with very low toxicity that retains potent anti-tumor activity in immune competent and immune deficient mouse tumor models
Cancer Research·2004· 2 cited
FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes
Nature Biotechnology·1997· 41 cited
Neutrophil functional responses depend on immune complex valency
Journal of Leukocyte Biology·1995· 24 cited
Role of the FcγR subclasses FcγRII and FcγRIII in the activation of human neutrophils by low and high valency immune complexes
Journal of Leukocyte Biology·1995· 24 cited
page 1 of 2Next →

Frequent Co-authors

Stephen D. Gillies(11), Kin-Ming Lo(11), Lan Yan(8), Yan Lan(5), Thore Hettmann(5), Stefan O. Mueller(5), Scott Lauder(5), Elizabeth R. Simons(5), Yaping Sun(4), Guozhong Qin(4), Bo Marelli(4), Yaping Sun(4), Lan Bo Chen(3), Robert M. Tighe(3), Richard Niederman(3), Gary J. Weil(3), Xiaomei Xu(3), Ravi Salgia(2), Jian‐Liang Li(2), Su Hao Lo(2)